Psychedelic companies feel that Compass Pathways results validate efforts to develop next-generation medicine for treating mental health issues.
Psychedelics
Psychedelics-Assisted Therapy: Effective, Economical AND Imperative
Psychedelic medicine is both extremely efficacious and highly cost-effective. It is also an absolute necessity to RESCUE the economy.
Novamind Signs LOI to Acquire Two Mental Health Clinics in Arizona
Novamind announces an LOI to add two Arizona mental health clinics to its treatment network.
12Media34!
atai Life Sciences reports its Q3 2021 financial results. Continued progress across 11 therapeutic research programs. Cash and equivalents of $430.3 million as of September 30, 2021.
Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights
Cybin Inc reports its fiscal Q2 results for 2021. Advanced several drug development candidates and received a Schedule I manufacturing license. Cash and equivalents of CAD$75.2 million as of September 30, 2021.
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
atai Life Sciences reports its Q3 2021 financial results. Continued progress across 11 therapeutic research programs. Cash and equivalents of $430.3 million as of September 30, 2021.
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline
MindMed announces its Q3 2021 results. Continued progress on R&D and pipeline development. Cash and equivalents of $178.6 million.
Bill aims to make Pennsylvania a national leader in psychoactive research
The bill would encourage research into psilocybin, the active ingredient in magic mushrooms.
DEA Boosts Psilocybin, MDMA And DMT Production Levels Again In Final Quotas For 2021
The Drug Enforcement Administration is again greatly increasing legal production quotas for illegal Schedule I drugs like psilocybin, MDMA and DMT.
Levitee Labs Signs Letter of Intent to Acquire a Chain of Specialty Addiction Pharmacies Located in British Columbia
Levitte Labs announce an LOI for the acquisition of 3 more pharmacies specializing in addiction.
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
Compass Pathways surprised and disappointed the market with its Phase IIb clinical results. Despite the immediate overall selloff on the news, the outlook for many psychedelic stocks is now BETTER.
Psilocybin therapy boosts cognitive and neural flexibility in depressed patients, study finds
Psilocybin-assisted psychotherapy appears to increase both cognitive and neural flexibility in patients with major depressive disorder, according to new research published in Translational Psychiatry.
Novamind Secures Insurance Coverage for Ketamine from Four Major Payors
Novamind reports that four health insurers are now covering its ketamine treatment for Treatment-Resistant Depression.
Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials
Numinus' Montreal and Vancouver clinics will be host for an extension of the MAPS Phase III clinical trial on MDMA-assisted therapy for PTSD.
Awe-inducing raves are linked to transformative experiences and social bonding, study finds
A study recently published in Frontiers provides new insight into the psychology of raves.